ACAD vs. INCY: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at ACAD and INCY, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Overview
INCY’s market capitalization of 13.25 billion USD is significantly greater than ACAD’s 3.51 billion USD, highlighting its more substantial market valuation.
With betas of 0.65 for ACAD and 0.68 for INCY, both stocks show similar sensitivity to overall market movements.
| Symbol | ACAD | INCY |
|---|---|---|
| Company Name | ACADIA Pharmaceuticals Inc. | Incyte Corporation |
| Country | US | US |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
| CEO | Catherine E. Owen Adams | Herve Hoppenot |
| Price | 20.95 USD | 68.45 USD |
| Market Cap | 3.51 billion USD | 13.25 billion USD |
| Beta | 0.65 | 0.68 |
| Exchange | NASDAQ | NASDAQ |
| IPO Date | May 27, 2004 | November 4, 1993 |
| ADR | No | No |
Historical Performance
This chart compares the performance of ACAD and INCY by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period.
Data is adjusted for dividends and splits.
Profitability
Return on Equity
ACAD
35.32%
Biotechnology Industry
- Max
- 72.39%
- Q3
- -6.30%
- Median
- -32.82%
- Q1
- -68.26%
- Min
- -147.61%
In the upper quartile for the Biotechnology industry, ACAD’s Return on Equity of 35.32% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
INCY
0.64%
Biotechnology Industry
- Max
- 72.39%
- Q3
- -6.30%
- Median
- -32.82%
- Q1
- -68.26%
- Min
- -147.61%
In the upper quartile for the Biotechnology industry, INCY’s Return on Equity of 0.64% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
Return on Invested Capital
ACAD
24.13%
Biotechnology Industry
- Max
- 48.74%
- Q3
- -10.68%
- Median
- -31.65%
- Q1
- -52.92%
- Min
- -113.69%
In the upper quartile for the Biotechnology industry, ACAD’s Return on Invested Capital of 24.13% signifies a highly effective use of its capital to generate profits when compared to its peers.
INCY
0.29%
Biotechnology Industry
- Max
- 48.74%
- Q3
- -10.68%
- Median
- -31.65%
- Q1
- -52.92%
- Min
- -113.69%
In the upper quartile for the Biotechnology industry, INCY’s Return on Invested Capital of 0.29% signifies a highly effective use of its capital to generate profits when compared to its peers.
Net Profit Margin
ACAD
22.97%
Biotechnology Industry
- Max
- 87.75%
- Q3
- -5.05%
- Median
- -103.44%
- Q1
- -1,032.77%
- Min
- -2,366.07%
A Net Profit Margin of 22.97% places ACAD in the upper quartile for the Biotechnology industry, signifying strong profitability and more effective cost management than most of its peers.
INCY
0.48%
Biotechnology Industry
- Max
- 87.75%
- Q3
- -5.05%
- Median
- -103.44%
- Q1
- -1,032.77%
- Min
- -2,366.07%
A Net Profit Margin of 0.48% places INCY in the upper quartile for the Biotechnology industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin
ACAD
23.58%
Biotechnology Industry
- Max
- 87.75%
- Q3
- -3.28%
- Median
- -115.26%
- Q1
- -1,188.86%
- Min
- -2,943.30%
An Operating Profit Margin of 23.58% places ACAD in the upper quartile for the Biotechnology industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
INCY
3.98%
Biotechnology Industry
- Max
- 87.75%
- Q3
- -3.28%
- Median
- -115.26%
- Q1
- -1,188.86%
- Min
- -2,943.30%
An Operating Profit Margin of 3.98% places INCY in the upper quartile for the Biotechnology industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
Profitability at a Glance
| Symbol | ACAD | INCY |
|---|---|---|
| Return on Equity (TTM) | 35.32% | 0.64% |
| Return on Assets (TTM) | 20.21% | 0.37% |
| Return on Invested Capital (TTM) | 24.13% | 0.29% |
| Net Profit Margin (TTM) | 22.97% | 0.48% |
| Operating Profit Margin (TTM) | 23.58% | 3.98% |
| Gross Profit Margin (TTM) | 92.04% | 92.28% |
Financial Strength
Current Ratio
ACAD
2.88
Biotechnology Industry
- Max
- 28.73
- Q3
- 13.97
- Median
- 6.31
- Q1
- 3.60
- Min
- 0.02
ACAD’s Current Ratio of 2.88 falls into the lower quartile for the Biotechnology industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
INCY
2.04
Biotechnology Industry
- Max
- 28.73
- Q3
- 13.97
- Median
- 6.31
- Q1
- 3.60
- Min
- 0.02
INCY’s Current Ratio of 2.04 falls into the lower quartile for the Biotechnology industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
Debt-to-Equity Ratio
ACAD
0.07
Biotechnology Industry
- Max
- 0.46
- Q3
- 0.22
- Median
- 0.06
- Q1
- 0.02
- Min
- 0.00
ACAD’s Debt-to-Equity Ratio of 0.07 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
INCY
0.01
Biotechnology Industry
- Max
- 0.46
- Q3
- 0.22
- Median
- 0.06
- Q1
- 0.02
- Min
- 0.00
Falling into the lower quartile for the Biotechnology industry, INCY’s Debt-to-Equity Ratio of 0.01 points to a conservative financing strategy. This results in lower financial risk but potentially limits strategic investments compared to more leveraged competitors.
Interest Coverage Ratio
ACAD
--
Biotechnology Industry
- Max
- 108.32
- Q3
- -0.55
- Median
- -8.49
- Q1
- -74.83
- Min
- -168.36
Interest Coverage Ratio data for ACAD is currently unavailable.
INCY
69.93
Biotechnology Industry
- Max
- 108.32
- Q3
- -0.55
- Median
- -8.49
- Q1
- -74.83
- Min
- -168.36
INCY’s Interest Coverage Ratio of 69.93 is in the upper quartile for the Biotechnology industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
Financial Strength at a Glance
| Symbol | ACAD | INCY |
|---|---|---|
| Current Ratio (TTM) | 2.88 | 2.04 |
| Quick Ratio (TTM) | 2.80 | 2.00 |
| Debt-to-Equity Ratio (TTM) | 0.07 | 0.01 |
| Debt-to-Asset Ratio (TTM) | 0.05 | 0.01 |
| Net Debt-to-EBITDA Ratio (TTM) | -1.68 | -4.67 |
| Interest Coverage Ratio (TTM) | -- | 69.93 |
Growth
The following charts compare key year-over-year (YoY) growth metrics for ACAD and INCY. These metrics are based on the companies’ annual financial reports.
Revenue Growth
Earnings Per Share (EPS) Growth
Free Cash Flow Growth
Dividend
Dividend Yield
ACAD
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ACAD currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
INCY
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
INCY currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio
ACAD
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ACAD has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
INCY
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
INCY has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | ACAD | INCY |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
Price-to-Earnings Ratio
ACAD
15.27
Biotechnology Industry
- Max
- 78.44
- Q3
- 48.98
- Median
- 20.50
- Q1
- 12.64
- Min
- 2.14
ACAD’s P/E Ratio of 15.27 is within the middle range for the Biotechnology industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
INCY
623.39
Biotechnology Industry
- Max
- 78.44
- Q3
- 48.98
- Median
- 20.50
- Q1
- 12.64
- Min
- 2.14
At 623.39, INCY’s P/E Ratio is exceptionally high, exceeding the typical maximum for the Biotechnology industry. This suggests the stock may be significantly overvalued compared to its peers and implies high market expectations that could be difficult to meet.
Forward P/E to Growth Ratio
ACAD
0.30
Biotechnology Industry
- Max
- 2.29
- Q3
- 1.10
- Median
- 0.49
- Q1
- 0.16
- Min
- 0.02
ACAD’s Forward PEG Ratio of 0.30 is within the middle range of its peers in the Biotechnology industry. This suggests a reasonable balance between the stock’s price and its expected growth, aligning with sector valuation norms.
INCY
-123.45
Biotechnology Industry
- Max
- 2.29
- Q3
- 1.10
- Median
- 0.49
- Q1
- 0.16
- Min
- 0.02
INCY has a negative Forward PEG Ratio of -123.45. This typically results from negative earnings or forecasts of declining future earnings, making the ratio not meaningful for valuation.
Price-to-Sales Ratio
ACAD
3.52
Biotechnology Industry
- Max
- 110.90
- Q3
- 59.76
- Median
- 11.33
- Q1
- 4.45
- Min
- 0.17
In the lower quartile for the Biotechnology industry, ACAD’s P/S Ratio of 3.52 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
INCY
3.00
Biotechnology Industry
- Max
- 110.90
- Q3
- 59.76
- Median
- 11.33
- Q1
- 4.45
- Min
- 0.17
In the lower quartile for the Biotechnology industry, INCY’s P/S Ratio of 3.00 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
Price-to-Book Ratio
ACAD
4.57
Biotechnology Industry
- Max
- 15.78
- Q3
- 7.44
- Median
- 3.31
- Q1
- 1.58
- Min
- 0.31
The P/B Ratio is often not a primary valuation metric for the Biotechnology industry.
INCY
3.62
Biotechnology Industry
- Max
- 15.78
- Q3
- 7.44
- Median
- 3.31
- Q1
- 1.58
- Min
- 0.31
The P/B Ratio is often not a primary valuation metric for the Biotechnology industry.
Valuation at a Glance
| Symbol | ACAD | INCY |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | 15.27 | 623.39 |
| Forward PEG Ratio (TTM) | 0.30 | -123.45 |
| Price-to-Sales Ratio (P/S, TTM) | 3.52 | 3.00 |
| Price-to-Book Ratio (P/B, TTM) | 4.57 | 3.62 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | 70.69 | 45.88 |
| EV-to-EBITDA (TTM) | 34.79 | 27.90 |
| EV-to-Sales (TTM) | 3.36 | 2.57 |